Advanced Cell Technology, Inc., a biotechnology company, focuses on the development and commercialization of human embryonic and adult stem cell technology in the field of regenerative medicine. Its embryonic stem cell research programs include cellular reprogramming, reduced complexity program, and stem cell differentiation research programs. The company’s cellular reprogramming involves in the development of therapies based on the use of genetically identical pluripotent stem cells generated by its cellular reprogramming technologies. Advanced Cell Technology, Inc. also generates stable cell lines with particular focus on blood lineage and vascular epithelial cell lines from hemangioblast cells. In addition, it is developing an autologous myoblast transplantation therapy to restore cardiac function in patients with advanced heart disease. The company’s stem cell-based therapy would provide treatment for a range of acute and chronic degenerative diseases. Further, it develops adult stem cell-based products that are specifically targeted at therapies for heart and other cardiovascular diseases. The company is headquartered in Marlborough, Massachusetts.

Oculus Innovative Sciences is a commercial healthcare company that develops and brings to market innovative solutions to medical problems that have the potential to improve the quality of life and care of patients worldwide. With the growth in access to medical services around the world, combined with a growing population of elderly and disabled people,  the rapidly expanding healthcare market is in need of new, more cost effective solutions to medical problems. Headquartered in Petaluma, California, Oculus is currently working on the clinical development of different applications of Microcyn® Technology, a patented solution/gel designed to prevent the growth of microorganisms with a wide variety of medical applications. The company has already begun distribution of various Microcyn® products in several markets, and continues to develop new treatments for a number of medical conditions and purposes, making it an exciting opportunity for investors interested in a company with existing products that also show great promise for futher medical applications.

MYOS Corporation is a company focused on the discovery, development and commercialization of therapeutic products that improve muscle health and performance. Its breakthrough discovery, MYO-T12^TM, inhibits the production of myostatin, a naturally occuring protein that suppresses rapid muscle growth and healing. When consumed, the formula reduces myostatin levels significantly in order to enhance muscle growth and repair, which makes it a breakthrough for both nutritional and pharmaceutical applications. The company produces a powder version of the substance that is used in the muscle building nutritional supplement MYO-X, packaged by distributor MHP, which is currently sold online at GNC.com. MYO-X is also is in the process of rolling out at GNC brick-and-mortar stores, and the company expects that it will begin shipping the product to other retailers in the near future. Additionally, the company has secured several patents related to the pharmaceutical applications of MYO-T12 for the prevention of muscle loss in both normal and chronically ill patients, and is pursuing exciting prospects in that market as well.